CPI and VaxEquity collaborate to advance the manufacturing of innovative vaccines and treatments
A grant of almost £700,000 has been awarded by Innovate UK to VaxEquity and CPI to help develop the manufacturing process of innovative vaccines and treatments.
The project will look to establish the best manufacturing processes and provide the best conditions for creating a first-of-its-kind saRNA flu vaccine. This vaccine will consist of the four WHO-mandated flu antigens encoded on a single saRNA construct. This approach – using saRNA rather than traditional flu vaccines – could result in reducing the time new treatments can come to market and make them more cost-effective.
saRNA is a new technology that has the potential to be used to develop medicines and vaccines. Compared with mRNA, saRNA has the ability to self-amplify. This means the medicines and vaccines produced could be delivered at a lower dose, thereby increasing availability and reducing costs.
